Testing SMART101 after half-matched stem cell transplant
Part of Blood & lymphatic, Brain & nervous system, Cancer, Genetic & congenital, Hormones & metabolism clinical trials.
This trial studies a new immune treatment called SMART101 given after a half-matched (haploidentical) stem cell transplant that uses post-transplant cyclophosphamide to prevent complications. It mainly checks safety, and may also look at how well SMART101 helps people with blood cancers recover after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older when you sign the consent form
- You have AML, ALL, or MDS and are planning a half-matched stem cell transplant
- Your heart pumping function is strong enough (left ventricular ejection fraction 40% or more)
- Your breathing tests are acceptable (your lung capacity or DLCO is at least 45% of predicted)
- Your liver and kidneys are working well based on routine blood tests
- You have not had a stem cell transplant from another person before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests SMART101 given after a T-cell–depleted (T-cell removed) donor bone marrow transplant. It aims to see if the treatment is safe and can help control certain high-risk blood cancers in children and adults.
This trial tests whether giving specially engineered donor T-cells after a stem cell transplant can help treat certain blood cancers like AML or MDS. The study is for people receiving a donor stem cell transplant for the first time.
This trial tests specially engineered donor T cells (TSC-100 or TSC-101) given after a stem cell transplant to help prevent cancer relapse in people with AML, MDS, or ALL. It is for patients who have a specific genetic marker (HA-1 or HA-2) and a matched donor.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
This trial tests a risk-adapted conditioning regimen (chemotherapy and/or radiation given before transplant) for people with certain blood cancers or bone marrow disorders who need a stem cell transplant from a donor. The goal is to tailor the conditioning strength to each patient’s risk, which may help improve outcomes and reduce side effects.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.